**The rate of ventilator-associated pneumonia fell from 15.2 cases per 1,000 ventilator days to 9.3 per 1,000, Dr. Victor Zayedfudim reported at the annual meeting of the Western Surgical Association.**

Complete compliance with a bundle of six measures designed to prevent VAP rose 90% during the same time frames, said Dr. Zayedfudim. The bundle had been implemented in 2002, he noted, but compliance was low and VAP rates had not gone down before the dashboard was introduced. The bundle requires spontaneous breathing trials by a screen saver “dashboard” with red alerts on computers in a surgical intensive care unit helped staff to increase compliance with measures to prevent ventilator-associated pneumonia and to reduce the incidence of these potentially deadly infections.

The rate of ventilator-associated pneumonia (VAP) fell from 15.2 cases per 1,000 ventilator days in July 2007 to 9.3 per 1,000 ventilator days during the 18 months before the dashboard was introduced in July 2007 to 9.3 per 1,000 ventilator days during the following 12 months, Dr. Victor Zayedfudim reported at the annual meeting of the Western Surgical Association.

Complete compliance with a bundle of six measures designed to prevent VAP rose 90% during the same time frames, said Dr. Zayedfudim of the department of general surgery at Vanderbilt University, Nashville, Tenn. The bundle had been implemented in 2002, he noted, but compliance was low and VAP rates had not gone down before the dashboard was introduced. The bundle requires spontaneous breathing trials by a screen saver “dashboard” with red alerts on computers in a surgical intensive care unit helped staff to increase compliance with measures to prevent ventilator-associated pneumonia and to reduce the incidence of these potentially deadly infections.


New state-specific data on smoking-attributable mortality (SAM) and years of potential life lost (YPLL) from the Centers for Disease Control and Prevention show that average annual overall SAM rates decreased during the two time periods by 44.4/100,000 population older than 15 years of age in Nevada, by 37.8/100,000 in California, and by a total of 33.4/100,000 in Virginia. Oklahoma was the only state that experienced an increase in SAM, by 26.9/100,000 (MMWR 2009;58:29-33).

Sex- and age-specific SAMs were calculated by multiplying the total number of deaths among adults older than 35 years from 19 diseases caused by cigarette smoking by estimates of the smoking-attributable fraction of preventable deaths for each disease.

Compared with 1996-1999, the average annual SAM rates declined in 2000-2004 among men in all states except Oklahoma, but increased among women in several states (Alabama, Arizona, Arkansas, Georgia, Indiana, Kansas, Kentucky, Louisiana, Michigan, Mississippi, North Carolina, Ohio, Oklahoma, South Carolina, South Dakota, Tennessee, Texas) and D.C. For every state, the annual number of smoking-related deaths was higher among males than among females, the CDC said. The release of these state-specific data follow a 2008urtles for Disease Control and Prevention show that average annual overall SAM rates decreased during the two time periods by 44.4/100,000 population older than 15 years of age in Nevada, by 37.8/100,000 in California, and by a total of 33.4/100,000 in Virginia. Oklahoma was the only state that experienced an increase in SAM, by 26.9/100,000 (MMWR 2009;58:29-33).

Sex- and age-specific SAMs were calculated by multiplying the total number of deaths among adults older than 35 years from 19 diseases caused by cigarette smoking by estimates of the smoking-attributable fraction of preventable deaths for each disease.

Compared with 1996-1999, the average annual SAM rates declined in 2000-2004 among men in all states except Oklahoma, but increased among women in several states (Alabama, Arizona, Arkansas, Georgia, Indiana, Kansas, Kentucky, Louisiana, Michigan, Mississippi, North Carolina, Ohio, Oklahoma, South Carolina, South Dakota, Tennessee, Texas) and D.C. For every state, the annual number of smoking-related deaths was higher among males than among females, the CDC said.
Smoking Deaths Are Down

“Predisnolone should be administered to preschoolers only when they are severely ill in the hospital. Intermittent, high-dose inhaled corticosteroids should not be used,” Dr. Bush said.

Dr. Jaychandran Panickar of the University of Leicester (England) and his associates assessed the efficacy of a 5-day course of oral prednisolone in children aged 10-60 months who presented to three British hospitals with an attack of wheezing preceded by an upper respiratory tract infection. These patients did not respond adequately to 10 puffs of albuterol administered through a metered-dose inhaler or nebulizer in the emergency department.

A total of 343 patients were randomly assigned to receive oral prednisolone and 344 to receive a matching placebo. There were no significant differences between the two groups in time to hospital discharge, number of further albuterol actuations given in the hospital, or Preschool Respiratory Assessment Measure (PRAM) scores at 4, 12, or 24 hours after presentation.

There were also no significant differences between prednisolone and placebo in parent-assessed 7-day symptom scores, time to return to normal activities, number of albuterol actuations given at home for 1 week, or number of readmissions for wheezing in 1 month.

The results were the same in the subgroup of children who were at high risk for developing asthma by school age, the patient group considered most likely to benefit from corticosteroids, Dr. Panickar and his colleagues reported (N. Engl. J. Med. 2009;360:129-138).

In the study of intermittent high-dose inhaled fluticasone, sponsored by GlaxoSmithKline, Dr. Francine M. Ducharme and his colleagues reported associations with adverse effects that are not yet clear, “are cause for concern and indicate that this management strategy should not yet be recommended for use in clinical practice,” Dr. Ducharme and her associates wrote (N. Engl. J. Med. 2009;360:339-353). In his editorial, Dr. Bush noted that oral corticosteroids have been “the bedrock of therapy” for preschoolers with acute virus-induced wheezing, even though their efficacy is controversial and their use is based on results for entirely different patient group: school-age children with asthma.

There can no longer be any justification for the administration of prednisolone to preschoolers without atopy who have episodic [viral] wheezing in either a community or hospital setting, unless a severe clinical course is anticipated,” he wrote (N. Engl. J. Med. 2009;360:409-410).

“It is disturbing to contemplate how many unnecessary courses of prednisolone have been given over the years, in good faith, because we all assumed that preschool children are little adults,” Dr. Bush noted.

Dr. Ducharme reported receiving research grants from GlaxoSmithKline, Merck & Co., and Nycomed International Management GmbH. Dr. Bush reported receiving grant support from Pharmaxis Ltd. Dr. Panickar reported no conflicts of interest, however, several of his associates reported associations with several pharmaceutical companies.

Dr. Bart Lesnick, FCCP, comments: A growing body of literature raises doubts as to the efficacy of long-term inhaled steroids, short-term high-dose inhaled steroids, and systemic corticosteroids in the treatment of recurrent viral induced wheezing in young children. It is unclear which children will progress to have full multi-trigger asthma. Thus, we may be overtreating a large number of children with our current practice.
Smoker With Bronchitis? Check for Undiagnosed COPD

Understanding the patients who are at greatest risk should help improve disease recognition.

BY MITCHEL L. ZOLER
Elsevier Global Medical News

PHILADELPHIA — Patients with a history of smoking and the symptoms of chronic bronchitis had a 26% prevalence of airflow obstruction consistent with chronic obstructive pulmonary disease, in a cross-sectional study of more than 1,200 people seen at primary care centers.

“Spirometry should be considered in anyone with a smoking history and respiratory symptoms,” Dr. Barbara P. Yawn and her associates said in a poster presented at the annual meeting of the American College of Chest Physicians. The finding highlights that physicians should be vigilant to the potential for airflow obstruction in patients with symptoms of chronic bronchitis, the researchers wrote. “Despite the increasing incidence of COPD worldwide, the vast majority of patients with the disease remain undiagnosed and underreported,” they added.

“Understanding the patients who are at greatest risk for having undiagnosed COPD should help improve disease recognition, diagnosis, and management,” Dr. Yawn said in a written statement. Increasing the targeted use of spirometry “will improve recognition of COPD,” added Dr. Yawn, a family medicine physician and director of research at Olmsted Medical Center in Rochester, Minn.

The prevalence of airflow obstruction consistent with COPD was determined in people aged 40 years or older who were patients at any of 40 U.S. primary care centers. Eligible participants had symptoms of chronic bronchitis and a smoking history of at least 10 pack-years. These participants were assessed using spirometry and two questionnaires. One questionnaire included the 12-item Short Form Health Survey, a modified respiratory questionnaire from the American Thoracic Society; and additional questions about disease, smoking history, and activities believed to cause breathing problems. The second questionnaire, the Lung Function Questionnaire, included seven questions on respiratory symptoms, smoking history, and age.

The average age of the 1,283 participants was 53 years (range 40-87 years), and 55% were women. Most were white (81%), and 17% were African American. Their average body mass index was almost 29 kg/m². In the 87% of participants who were current smokers, the average number of pack-years was about 40, with a range of 10-172.

Airflow obstruction indicative of COPD, defined as forced expiratory volume in 1 second divided by forced vital capacity (FEV₁/FVC) of 70% or less following bronchodilator (albuterol) treatment, occurred in 26% of the patients. The prevalence of undiagnosed obstructive lung disease—defined as an FEV₁/FVC of 70% or less before bronchodilator treatment—was 34%. Bronchodilator reversibility was absent in 91% of participants.

Slight dyspnea, defined as shortness of breath when hurrying on level ground or when walking up a slight hill, existed in 47%. Coughing four to six times a day at least 4 days per week was reported by 79%, and 75% reported a whistling sound in their chests.

The analysis also showed that the prevalence of a breathing impairment suggestive of COPD increased with age.

Among the youngest people in the study, those aged 40-49 years, an FEV₁/FVC below 70% occurred in 16%. The prevalence of this COPD marker rose to 23% among people aged 50-59 years, to 46% among those aged 60-69 years, and to 52% in those aged 70 years or older.

GlaxoSmithKline funded the study, and one of Dr. Yawn’s associates was a GSK employee. Dr. Yawn and her other associates said that they had no conflicts of interest to disclose.

Dr. Philip Marcus, MPH, FCCP, comments: This is yet another reminder of the need for screening patients at risk for COPD, especially smokers, to document the presence of airflow obstruction and then to be able to counsel patients concerning the importance of smoking cessation.

In addition, early treatment may help improve quality of life. This information needs to be widely disseminated to the primary care community, essentially the first line for intervention.

Also, the wording in this study may be confusing because, as we all know, chronic bronchitis is one of the presentations of COPD, and if one has chronic bronchitis, one has COPD.

Longer Life Spans Tied to Reduced Air Pollution

B Y MARY ANN MOON
Elsevier Global Medical News

Increases in life expectancy during the 1980s and 1990s were associated with reductions in fine-particle air pollution in 51 metropolitan areas across the United States, according to a report in the New England Journal of Medicine.

Specifically, when the concentration of particulate matter with an aerodynamic diameter less than or equal to 2.5 micrometers (PM₂.⁵) decreased by 10 mcg/m³ in study areas, life expectancy rose by about 1 year, reported C. Arden Pope III, Ph.D., of Brigham Young University, Provo, Utah, and associates.

Although it might be impossible to tease out the influence of numerous individual factors on health risks and benefits over time, the findings “suggest that the individual effect of reductions in air pollution on life expectancy was as much as 15% of the overall increase,” said the researchers (N. Engl. J. Med. 2009;360:413-5).

They assessed air pollution data collected from 211 counties surrounding the target metropolitan areas for one period in the late 1990s and early 2000s, and compared it with data from the late 1990s and early 2000s in the same counties. They also assessed life expectancy estimates for the corresponding areas and time periods, as well as socioeconomic and health data that might confound life expectancy estimates, such as proxy variables for the prevalence of smoking and access to health care. In several statistical models, life expectancy rose as fine-particle pollution declined. And “in a variety of related sensitivity analyses, the effect estimate for a change in PM₂.⁵ was quite robust,” Dr. Pope and colleagues said.

“Previous prospective cohort studies, using measures of ambient concentrations of pollutants and controlling for smoking and other individual risk factors, have suggested similar improvements in survival and life expectancy, on the basis of indirect estimates,” they wrote.

“The results of our population-based analysis corroborate these previous findings,” they noted.

In an editorial comment that accompanied this report, Daniel Kweder, Ph.D., of the McLaughlin Center for Population Health Risk Assessment at the University of Ottawa, said that this “pioneering” work provides direct confirmation of the population health benefits of mitigating air pollution and greatly strengthens the foundation of the argument for air-quality management.”

The findings mirror those of previous investigations in the Netherlands, Finland, and Canada that showed that increases in ambient PM₂.⁵ concentrations of 10 mcg/m³ correlated with reductions in life expectancy of 0.8-1.37 years, Dr. Kweder said (N. Engl. J. Med. 2009;360:413-5).

A coauthor on the report disclosed receiving grant support from the Health Effects Institute. Dr. Kweder reported serving on a university-industry partnership program, and as CEO and chief risk scientist at Risk Sciences International.
Look for Rheumatic Disease in ILD

BY SHERRY BOSCHERT
Elsevier Global Medical News

SAN FRANCISCO — Clinicians detected underlying rheumatic disease in 17 of 28 patients referred to a multidisciplinary clinic for interstitial lung disease.

The evaluations changed the diagnosis in 11 of the 28 patients, including 4 of 15 who had been referred for idiopathic interstitial lung disease and 7 of 13 who had been referred for rheumatic disease related to interstitial lung disease (ILD).

As a result, clinicians changed therapy for 14 (50%) of the patients, Dr. Flavia V. Castelino and her associates reported at the annual meeting of the American College of Rheumatology.

All patients with ILD should be evaluated by a rheumatologist, said Dr. Castelino of Massachusetts General Hospital, Boston.

Distinguishing between ILD that is idiopathic versus related to rheumatic disease is important because the former carries a worse prognosis, and the response to treatment may differ, she said. A separate retrospective study of 362 cases of ILD found 5-year survival rates of approximately 40% with idiopathic disease and approximately 70% with cases that were associated with rheumatic disease (Am. J. Resp. Crit. Care Med. 2007;175:705-11).

The difference in prognosis is thought to be related to the major lung histopathology, previous data suggest. Nonspecific interstitial pneumonia was present in 4 (9%) of 47 patients with idiopathic ILD and in 23 (83%) of 28 patients with undifferentiated connective tissue disease and interstitial lung disease in one study (Am. J. Resp. Crit. Care Med. 2007;176:691-7).

A separate previous study of 39 cases of ILD found that community physicians were more likely to diagnose it as idiopathic disease, compared with retrospective diagnoses from a multidisciplinary academic team review by pulmonologists, radiologists, and pathologists (Am. J. Resp. Crit. Care Med. 2007;175:1084-60).

In the current prospective study of patients referred by pulmonologists over an 8-month period to a new multidisciplinary clinic at Brigham and Women’s Hospital, Boston, all patients were evaluated by a pulmonologist and a rheumatologist, who took a complete history and physical examination (including capillary microscopy) and reviewed laboratory and serologic data. They reviewed available imaging and pathologic specimens in consultation with a dedicated radiologist and a pathologist experienced in interstitial lung disease.

Additional serologic tests, imaging, or biopsies were performed at the discretion of the clinic physicians. They initiated or changed therapy in collaboration with the referring physician.

Evaluations by a rheumatologist significantly affected diagnoses because of additional serologic testing and because the rheumatologist was able to elicit subtle clues suggestive of a rheumatologic diagnosis. Recognition of “mechanic’s hands,” periungual erythema, abnormal capillary microscopy, and inflammatory arthritis led to new diagnoses including antinuclear antibodies, systemic sclerosis, rheumatoid arthritis–associated ILD, and mixed connective tissue disease.

The cohort was half female, with a median age of 63 years and a history of smoking in 23 (82%) of patients.

The multidisciplinary interstitial lung disease clinic now meets weekly and has evaluated an additional 28 patients. In this group, diagnoses were changed in eight patients, Dr. Castelino said.

The investigators reported that they had no potential conflicts of interest related to this study.
BY BRUCE JANCIN

Elsevier Global Medical News

NEW ORLEANS — The risks of pneumonia and other serious infectious and septic complications of traumatic injury climb steadily in age-dependent fashion.

This finding from an analysis of the world’s largest trauma registry suggests that the immune response to trauma varies with the age of the patient, and that the neuroendocrine axis is involved in this immunoactivation, Dr. Christian D. McClung observed at the annual scientific sessions of the American Heart Association.

He reported on 857,046 patients aged 5-89 years included in the American College of Surgeons National Trauma Data Bank for 2000-2004.

The patients in the database were hospitalized at more than 600 participating trauma centers, with a median 3-day length of stay. The mean age of the study population was 40 years. Two-thirds were male. The mortality rate was 4.4%.

Pneumonia was a complication of trauma in 1.6% of cases, acute respiratory distress syndrome in 0.5%, and bacteremia in 0.13%, according to Dr. McClung, an emergency physician at Los Angeles County–USC Medical Center, Los Angeles.

The risks of pneumonia, bacteremia, and acute respiratory distress syndrome rose with each decade of age in a multivariate logistic regression analysis adjusted for potential confounders including age, sex, injury severity score, trauma mechanism, and days on a ventilator.

The 56,680 children aged 5-12 years in the study served as the comparison group.

These risk figures are probably underestimates, since it’s likely that posttraumatic complications are underreported, Dr. McClung noted.

Infectious Complications of Trauma Rise With Age

6:32 a.m. Another moment to breathe.

Another day to enjoy life with Zemaira®

**Fast**—The shortest infusion time

**Pure**—The only Alpha-1 augmentation therapy approved by the FDA as highly purified

**Convenient**—Room-temperature storage

**Supported**—Extensive patient services

Pure. And simple.
PULMONARY MEDICINE

Infliximab Benefits Sarcoidosis Patients

BY MITCHEL L. ZOLER

Elsevier Global Medical News

Philadelphia — Patients with sarcoidosis who have the most severe lung disease stand to benefit the most from treatment with a tumor necrosis factor (TNF) antagonist, said Dr. Daniel Culver, FCCP, said at the annual meeting of the American College of Chest Physicians.

Prior to the time being, the tumor necrosis factor (TNF) antagonist that is most beneficial to use for sarcoidosis is infliximab (Remicade), because it has "the best track record," said Dr. Culver, a clinician in the Respiratory Institute at the Cleveland Clinic.

On the basis of treatment results reported so far, the best candidates for infliximab treatment among pulmonary sarcoidosis patients are those who have more severe physiologic derangement, those with disease duration of longer than 2 years, and patients with dyspnea as a prominent symptom, he said.

For the most part, however, sarcoidosis patients have not shown substantial improvement with infliximab treatment, according to Dr. Culver. A more realistic treatment goal is slowing disease progression.

The most extensive experience with successful infliximab treatment in sarcoidosis is in patients with pulmonary involvement.

The treatment has also shown some efficacy for treating extrapulmonary disease, such as patients who have central nervous system or skin involvement.

In some of these sarcoidosis patients, the benefit of infliximab has waned over a period of time, other patients have experienced a durable effect. One very responsive group of patients with skin involvement has been those with lupus pernio. In one recent series, 90% of sarcoidosis patients with lupus pernio improved with infliximab treatment, Dr. Culver said.

Despite promising reports that support using infliximab in sarcoidosis patients, there are still few data on the best dosage, and dose escalation has not been useful so far in patients who don’t respond to infliximab. The best treatment interval seems to be an injection every 4-8 weeks.

Concurrent treatment with methotrexate appears to enhance the benefit of infliximab from immunosuppressant drugs, and also reduces the risk that patients will develop an immune reaction to the injected drug.

As with any anti-TNF drug, care must be taken about the risk of activating latent tuberculosis. It is advisable to screen patients for tuberculosis before starting infliximab treatment, and to watch for an atypical infection presentation, Dr. Culver said.

Ideal candidates for treatment with any different anti-TNF drug are those who may develop side effects from infliximab or initial responders whose reponse wanes over a period of time. However, far less experience exists for treating sarcoidosis patients with adalimumab (Humira) or certolizumab (Cimzia) Etanercept (Enbrel) does not appear to be useful for treating sarcoidosis.

Dr. Culver also cautioned that none of the anti-TNF drugs have a labeled indication for treating sarcoidosis, and there have been no reports from placebo-controlled studies of agents other than infliximab in sarcoidosis patients.

However, using an anti-TNF drug makes sense, he said, because TNF levels are increased in sarcoidosis patients, and TNF plays a role in granuloma formation.

 Patients who don’t respond to a TNF antagonist may include those who have a low baseline level of C-reactive protein, patients who are smokers, patients with a genetic polymorphism, and those whose disease is not as strongly mediatated by TNF.

Dr. Culver said that he has received no corporate funding or payments relevant to these drugs.

The best candidates are those with more severe physiologic derangement, disease duration of at least 2 years, and dyspnea as a prominent symptom.
respiratory therapists; administration of the Richmond Agitation Sedation Scale by physicians and registered nurses; and head of bed elevation, oral care, dental hygiene, and hypopharyngeal suction by registered nurses. All critically ill patients received stress ulcer prophylaxis and deep venous thrombosis prophylaxis,” he added.

As described by Dr. Zaydfudim, the dashboard tracks compliance in real time for every patient in the ICU. Each measure in the bundle corresponds on the dashboard to a box in a row assigned to each patient. A green box tells the staff that the patient’s care is up to date with that item. A yellow box indicates that compliance for that item is about to expire. A red box means the patient’s care no longer meets the standard set forth in the bundle.

All computers in the ICU are equipped with the screen saver, which appears for everyone to see whenever a computer is not being used.

The closed, intensivist-run, 21-bed surgical ICU where the dashboard was tested is in a tertiary referral center that admits about 1,300 patients per year. Except for the average APACHE II score, which increased from 17.8 to 22, and a small rise in body mass index, Dr. Zaydfudim said patient case mix did not change significantly during the study.

The rate of bloodstream infection was similar before and after the dashboard: 4.5 per 1,000 catheter days and 5 per 1,000 catheter days, respectively.

VAP is the most common nosocomial infection in ventilated patients, he noted. It accounts for 60% of hospital-acquired pneumonia deaths, prolongs hospital stays by 4 days, and increases direct hospital costs by about $40,000 per patient.

The study defined VAP by the following criteria: mechanical ventilation lasting more than 48 hours; fever higher than 38.5°C and/or leukocytosis greater than 12,000 cells per microliter, and/or infiltrate on chest radiograph; and positive bronchoalveolar lavage culture with greater than $10^5$ cfu/mL.

Despite the VAP reduction achieved with the dashboard, Dr. Zaydfudim said further efforts are still needed to meet a VAP goal of 4.1 cases or less per 1,000 ventilator days, based on data published by the Centers for Disease Control and Prevention (Am. J. Infect. Control 2007;35:290-301). This led to a discussion of whether an across the board standard based on hospital reporting is realistic if surgical and trauma ICUs carry a higher risk of VAP compared with medical units.

“I am not sure we are ready to accept those benchmarks as stated,” said Dr. Charles Wright Pinson, H. William Scott Professor of Surgery at Vanderbilt and senior author of the study.

The presence of a complication is directly proportional to how hard you look for it. And so I would submit that people who report very low VAP rates, like zero VAP rates, are not looking for it very hard,” Dr. Pinson said, questioning whether generalized targets are realistic for specific subgroups of surgical ICU patients. The Vanderbilt surgical ICU was limited to general surgery, vascular surgery, and patients from surgical subspecialties such as thoracic, plastic, orthopedics and otolaryngology, as well as transplant patients, he noted; it did not include cardiac and trauma patients.

Asked how Vanderbilt kept staff motivated once the dashboard was no longer a novelty, he said, “We set this up as a management goal, so all personnel in this unit were responsible for the outcome.”

He did not have data on cost of the intervention, but said the unit initially tried to make the intervention work with a paper dashboard. Putting the dashboard on a screen saver, where it serves as a constant reminder, was helpful, he said.

Dr. Zaydfudim disclosed no conflicts of interest.

Dashboard Improves Compliance

Dashboard Improves Compliance VAP • from page 1

“The power of negative thinking

In treatment of gram-negative infections caused by susceptible gram-negative microorganisms

AZACTAM is indicated for

• Complicated and uncomplicated urinary tract infections, lower respiratory tract infections, septicaemia, skin and skin-structure infections, intra-abdominal infections, and gynecologic infections

• Adjunctive therapy to surgery in the management of infections caused by susceptible organisms. Effective against most commonly encountered gram-negative aerobic pathogens seen in general surgery

Important Safety Information: AZACTAM is contraindicated in patients with known hypersensitivity to aztreonam or any other component in the formulation.

While causality of serious infection with other beta-lactam antibiotics is rare, this drug should be administered with caution to any patient with a history of hypersensitivity to beta-lactams.

Clostridium difficile-associated diarrhea (CDAD) occurs with use of nearly all antibacterial agents, including AZACTAM, and severity ranges from mild diarrhea to fatal colitis. Antibacterial agent use alters the normal flora of the colon leading to overgrowth of C difficile. Consider CDAD in all patients presenting with diarrhea following antibacterial use. If CDAD is suspected or confirmed, ongoing antibacterial use not directed against C difficile may need to be discontinued.

In patients with impaired hepatic or renal function, appropriate monitoring is recommended during therapy.

Please see brief summary of prescribing information on adjacent page.
Higher CRP Levels Linked to Better ARDS Outcomes

BY BRUCE JANCIN
El Dorado Global Medical News

New Orleans — Critically ill patients with acute respiratory distress syndrome who had higher CRP levels in the laboratory at admission were significantly more likely to have a better outcome than those who had lower CRP levels, according to a poster presented here at the American Thoracic Society conference.

CRP, or C-reactive protein, which is a biomarker of systemic inflammation, is always a bad thing. A high CRP level has previously been shown to predict worse outcomes in patients with cardiovascular disease, and several other infections and diseases, Dr. James Januzzi Jr. said at the annual scientific sessions of the American Heart Association.

When the group of well-characterized patients with acute respiratory distress syndrome, those with lower CRP concentrations were sicker, and CRP concentrations were significantly lower among those patients who died, and this association was present in a graded fashion such that patients with the highest CRP values had the lowest event rates. CRP concentrations were independently inversely predictive of survival, he said.

So we conclude that our finding, which we’re currently in confirming a much larger cohort of patients with ARDS, paradoxically seems to support the beneficial role of CRP in ARDS,” said Dr. Januzzi of Massachusetts General Hospital, Boston.

The 177 ARDS patients were mostly middle-aged adults with a mean age of 57 years. At the time of admission, mean positive end-expiratory pressure was 12 mm Hg and mean median pressure was 15 mm Hg. The mean CRP was 155 mg/L. In the 70 patients who died within 60 days, the median value was 155 mg/L, compared with 175.6 mg/L in the 107 survivors. With use of an optimal cut point of 226 mg/L, the 130 patients with a CRP below that threshold had a 60-day survival of only about 25%, compared with more than 60% survival in the group with a CRP level greater than 226 mg/L.

After a Cox proportionate hazards analysis was used to adjust for age, APACHE III score, liver disease and other relevant comorbid conditions, and CRP lowering corticosteroid therapy, CRP level remained a significant predictor of mortality. Indeed, a practical clinical take-home point in the study was that a median CRP level of 226 mg/L was associated with a 50% reduction in the likelihood of mortality within 60 days, Dr. Januzzi noted.

The median APACHE III score among the 107 survivors was 73, compared with 90 in patients who died within 60 days. Yet in the multivariate adjusted analysis, APACHE III scores were no longer significantly associated with outcome. In contrast, CRP level was still a significant predictor.

“This paradoxical finding regarding CRP and ARDS prognosis may be explained by basic science models, he said.

“We are forced to actually look—perhaps against our will as cardiologists—at the basic science data, which suggest that CRP may actually be beneficial in experimental models of acute lung injury. It has been shown that CRP inhibits neutrophil chemotaxis and reduces alveolitis, and that CRP overexpression leads to a systemic response to alveolitis and acute lung injury. So it may very well be that we are seeing a clinical correlate with these basic science models,” Dr. Januzzi said.
Catheter Line Protocols Slash CA-BSIs in Children

BY DENISE NAPOLI
Elsevier Global Medical News

The overall rate of catheter-associated blood stream infections is 1.2 per 1,000 line-days at the critical care unit of Children’s National Medical Center in Washington, D.C. Compared with the national 2006 pooled mean of 5.3 infections per 1,000 central line-days, “that’s pretty good,” said Dr. Heidi Dalton, who heads the unit.

Recently the unit went 197 days without any patients developing catheter-associated blood stream infections. “The secret of the unit’s success, according to Dr. Marlene Miller, is an approach that focuses on line maintenance rather than line insertion.”

In the adult population, a catheter line is accessed relatively infrequently, and infection rates are dramatically reduced after initiating relatively simple standardization policies. But in children, catheter lines are accessed much more frequently—more than 30 times per day in some cases, according to Dr. Miller.

“In children, we’ll draw all our blood samples from the line so that the child doesn’t have to have another painful needle stick. Every one of these ‘creature comforts’ to minimize the pain is extremely important to these [pediatric] patients,” said Dr. Miller, who is cochair of the Catheter-Associated Blood Stream Infections Project, run by the National Association of Children’s Hospitals and Related Institutions (NACHRI).

In addition, because lines are difficult to insert in children, they are often left in longer. “Although the child may look good today, tomorrow they might not look so good. Since it is very hard to put these types of lines in children, especially younger ones, we carefully consider when to remove the line.”

Another variable is the location of line placement. With young children, “we might be hesitant to put a line in the neck region where they can grab it,” said Dr. Miller, who is also vice chair of Quality and Safety at Johns Hopkins Children’s Center in Baltimore.

The frequency of access to pediatric lines and the duration of placement mean that best practices for line insertion aren’t enough, she said. Pediatric critical care teams seeking to lower their catheter-associated blood stream infection (CA-BSI) rate must focus on line maintenance.

Children’s National Medical Center succeeded in achieving reduced rates after becoming 1 of 27 hospitals around the country that enrolled in phase I of the NACHRI collaborative when it was initiated in October 2006. Since then, the collaborative has expanded to include more than 60 pediatric intensive care units.

Overall, according to the NACHRI Web site, the 27 phase I participants have tallied a 43% decrease in CA-BSIs in the first 12 months of the program, $9 million in cost savings related to an estimated 275 prevented infections, and the likely prevention of dozens of deaths.

The NACHRI program provides hospitals with ‘bundled’ or prompts for intensive care unit staff to ask themselves each time a line is accessed. For example, one of the prompts asks whether any medications can be converted from venous to oral administration. Dr. Miller said. Another bundle offers evaluation tools and encourages critical care teams to frequently assess whether the line can be removed.

Nurses and other staff are also instructed about the cleaning and changing of the catheter line’s cap (different protocols apply according to whether the line has most recently been used for feeding, medication, or blood drawing), the changing of the dressing at the insertion site, and the methods of clearly communicating the status of each aspect of central line care for each patient to the nurses in the next shift.

“It’s a lot of work, but this is the only statistically significant predictor we have: If you do maintenance care better, you’re significantly more likely to have a lower CA-BSI rate in pediatric patients,” Dr. Miller said. Dr. Dalton added that the hospital’s adoption of a minocycline/rifampin-impregnated line designed for children, the Cook Spectrum (Cook Medical), has also played a major role in their success at reducing BSIs. In addition, contributing factors have been the switch to chlorhexidine scrub and the use of Biopatch (Johnson & Johnson Inc.) at the site of insertion, both of which are recommended by the NACHRI collaborative.

Just participating in the collaborative drives infection reductions, she added. “All the hospitals in that collaborative make their data transparent [to each other],” she said. “So you’re not just ‘unit 22.’ Everyone knows [unit 22] is Children’s National Medical Center data. The peer pressure of the network has really made a sustained improvement in our infection rate.”

Dr. Dalton declared that she has no conflicts to disclose in relation to her use of the Cook Spectrum catheter, Biopatch, or chlorhexidine.

For more information about the NACHRI collaborative, visit www.childrenshospitals.net.

CALL FOR ABSTRACTS

Submission Is Free

Be part of CHEST 2009 by submitting an abstract of your original investigative work for presentation before thousands of physicians. Authors of accepted abstracts will be eligible for The CHEST Foundation investigative awards.

SUBMIT ABSTRACTS NOW

www.chestnet.org

Submission Deadline: May 4

CELEBRATING 75 YEARS OF INSPIRATION

1935 - 2009
The IMPACT DC Asthma Clinic: Breaking the Cycle of ED Recidivism Among Urban Pediatric Patients With Asthma

While EDs are effective at managing exacerbations, the care rarely extends beyond the acute episode.

With a grant from the Robert Wood Johnson Foundation received in 2001 (Rachelefsky et al. Pediatrics 2006; 117:537), we developed and evaluated an ED-based intervention (the IMPACT DC Asthma Clinic [Improving Pediatric Asthma Care in the District of Columbia]) that successfully reduced dependence on EDs for episodic care of asthma, while also decreasing morbidity and improving asthma-related quality of life among a cohort of low-income, urban, and largely minority children with moderate to severe asthma and a history of ED recidivism (Teach et al. Arch Pediatr Adolesc Med 2006; 160:535). We have since sustained and grown this multifaceted approach to addressing disparities in asthma care and outcomes among children in our community.

Pediatric asthma is a disease marked by dramatic disparities in care and outcomes, with poor and minority children bearing a disproportionate share of the overall morbidity (Grant et al. Arch Pediatr Adolesc Med 2006; 160:535). We have since sustained and grown this multifaceted approach to addressing disparities in asthma care and outcomes among children in our community.

Pediatric asthma is a disease marked by dramatic disparities in care and outcomes, with poor and minority children bearing a disproportionate share of the overall morbidity (Grant et al. Arch Pediatr Adolesc Med 2006; 160:535). We have since sustained and grown this multifaceted approach to addressing disparities in asthma care and outcomes among children in our community.

Pediatric asthma is a disease marked by dramatic disparities in care and outcomes, with poor and minority children bearing a disproportionate share of the overall morbidity (Grant et al. Arch Pediatr Adolesc Med 2006; 160:535). We have since sustained and grown this multifaceted approach to addressing disparities in asthma care and outcomes among children in our community.
Continued from previous page

within 15 days of their ED discharge.

The participants were predominantly African-American (86%) and economically disadvantaged. Reliance on the ED was high, with more than half having >3 other ED visits for asthma in the prior 12 months. Despite the high morbidity of this cohort, just under 25% of participants reported use of inhaled corticosteroids (ICS), and just under 21% reported use of a written asthma action plan.

A single visit to the IMPACT DC Asthma Clinic was associated with improved outcomes in multiple domains. One month after the visit, for example, patients in the intervention group were significantly more likely to have used a written asthma action plan, to report daily use of controller medications, and to use a spacer with their metered-dose inhalers. Over the 6-month follow-up period, patients in the intervention group had significantly fewer ED visits than patients in the control group (0.64 vs. 1.19 visits respectively, adjusted RR=0.54 [0.40, 0.72]). Patients in the intervention group also had significantly fewer total unscheduled visits to any source (ED or elsewhere) [1.39 vs 2.14, adjusted RR=0.60 (0.46-0.77)]. Perhaps most importantly, the intervention group showed significant improvements in several measures of quality of life that largely persisted over the 6-month follow-up period.

The Clinic’s operations are now funded by a mixed portfolio that includes fee-for-service and philanthropy. Medical coverage is provided by pediatric emergency medicine physicians, general pediatrics, pediatric hospitalist physicians, and a pediatric nurse practitioner.

Comment

The IMPACT DC Asthma Clinic has become a unique source of care for patients with asthma in DC by targeting children who are heavily dependent on EDs for episodic care. This provision of a comprehensive source of asthma education, medical care, and care coordination is designed to transition them to more effective longitudinal asthma care in their primary care medical homes. The model grew out of the idea that the ED can and should take a proactive role in reducing asthma morbidity in our community.

While ED visits are a downstream marker of the asthma epidemic, we recontextualized the role of our ED as an important point of intervention, especially given its place as a trusted source of asthma care for many disadvantaged, urban, and minority children.

While the IMPACT DC Asthma Clinic has been implemented and expanded to become a key element of the asthma care plan at CNMC, we have not reproduced its success in other communities or in other environments. We believe that an important aspect of our success is that our large urban ED sees sufficient numbers of asthma visits to provide a steady flow of referrals and that the families seen in our ED are very bonded to it and return to our clinic in large numbers. In addition, our leadership in the ED is supportive of our novel approach, even though our primary goal is to reduce subsequent visits to the department. Another key factor is our own commitment to sustaining, expanding, and improving this program.

While there remains a debate on the appropriateness of the expanded role of the ED in asthma management (Singer et al. Ann Emerg Med 2005; 45:295), we believe that our program is a successful example of how an ED can improve asthma care and outcomes within a disadvantaged urban pediatric population.
Continued from previous page

Cultural Diversity, Disaster Response, Home Care

Cultural Diversity in Medicine

This NetWork draws upon the diversity and expertise of the ACCP membership in the education and care of patients with similar characteristics, habits, and traditions who may be under served by mainstream medicine. As part of its mission, the NetWork focuses on issues specific to lung health and palliative care and end-of-life issues in these populations. The members of this NetWork have a special passion in matters related to diversity, cultural competency, and education, and addressing health-care disparities.

The NetWork’s completed projects include a speaker’s kit, Lung Health in Minorities, the “Chest Coach” mentoring program, and a postgraduate course on cultural competence featured during CHEST 2006. The NetWork has always included palliative and end-of-life issues on its agenda as it develops educational offerings for the annual CHEST meetings and represents the ACCP in collaborative efforts with other organizations. Ongoing activities include representation by Drs. Shek Hassan, FCCP, and Allen Goldberg, Master FCCP, as ACCP representatives on the AMA’s Commission to End Healthcare Disparities.

Looking toward the future, the NetWork is strengthening its commitment to improve the education about and treatment of lung health among the economically and socially disadvantaged and those with disproportionately poorer health outcomes. The NetWork is looking to produce a resource of cultural competence initiatives in collaboration in this area and other organizations. The proposed compendium would identify resources, activities, and key individuals to the discussion on cultural competence. Development and dissemination of the resource to both caregivers and patients would continue the course set by ACCP Immediate Past President, Dr. Alvin Thomas, Jr., FCCP, which he described during CHEST 2007. More information about our NetWork is available at www.chestnet.org/networks/cultural_diversity/index.php.

Dr. Walfredo Leon, FCCP
Cultural Diversity in Medicine NetWork

Disaster Response

The US Department of Defense (DOD) released a directive stating effective nation reconstruction must include health care. Because of the current emphasis on the US military, several recent humanitarian missions have included non-DOD providers with non-governmental organizations serving as a major source of medical personnel.

“Project Hope” has partnered on such missions around the world. With Project Hope, Dr. Reed joined the sophisticated hospital ship, USNS COMFORT in 2007, on its mission to South America and visited three countries: Trinidad/Tobago, Guyana, and Surinam. In Trinidad, a community center served as our clinic. Patients and, in some cases, doctors came to garner opinions. Over 3 days, we performed highly complex adult and pediatric surgeries. Local surgeons observed and prepared for postoperative care. It was an efficient use of resources.

In Guyana and Surinam, the health care seemed political. US relations appeared strained. Our team was informed that there would be no local follow-up care. This severely limited the scope of surgery offered. Patients were transferred directly to home care postoperatively. Many patients who could benefit from our expertise were not helped.

Winning “hearts and minds” through health is not yet an American strength. Cuban physicians have done health outcomes that fit within world standards. They select and train physicians early in medical school. China provides money to build and equip clinics throughout the world. Despite frustrations, the experience was rewarding. Many believe the US will continue to use health diplomacy to improve its world image. Clearly, civilians will be needed. However, there are concerns. Combining humanitarian care with a military presence blurs the line between altruism and national interest. Which agenda is more important? Who is in charge? How can civilians and the military cooperate? Hopefully, it will evolve as the world is shrinking and a “hand held is a heart won.”

CAPT Dennis Amandim, MC, USN, FCCP
Disaster Response NetWork

Home Care

Since 2000, there has been an average annual increase in the incidence of natural disasters by 8.4% per year (Scheuren J-M, et al. Annual Disaster Statistical Review: The Numbers and Trends 2007. US Agency for International Development’s Office of Foreign Disaster Assistance [OFDA]: Belgium). Much emergency preparedness has focused on management of disaster-related acute illness. Members of the ACCP’s Disaster Response NetWork served on the task force that recently published guidance for mass critical care delivery (Devereaux et al. Chest Continued on following page)

In physician practice performance. A similar approach has been advocated by the Federation of State Medical Boards, and renewal of state licenses may require documentation that a physician has participated in quality improvement activities, as well as those that certify competence.

Where does the ACCP fit into this? The College is well known for its high quality, clinically relevant continuing education courses. In addition to our regularly scheduled courses, one of our finest educational offerings is ACCP-SEEK, the Self-Education and Evaluation of Knowledge workbook, published annually.

Changes are being made in these educational offerings recognizing the need to demonstrate to The Accreditation Council for Continuing Medical Education, our certifying organization, that participants’ knowledge, competence, and performance are improved based on participation in ACCP educational programs.

In response to the modification of the maintenance of certification process and the move toward external grading of our clinical practice by outside agencies, the College has embarked on several additional projects. To address the issue of clinical competence, the College has added a state of the-art simulation center to the headquarters in Northbrook, IL. The ACCP Simulation Center for Advanced Clinical Education is designed to enhance your learning in a hands-on clinical environment. The recently expanded center features a variety of simulation exercises, so participants can apply their knowledge and actively practice clinical skills in realistic scenarios. The center features technologically sophisticated equipment and an experienced faculty to assist participants with advancing their cognitive, technical, and behavioral skills needed for optimal patient care across a variety of situations. The College has been building real life clinical scenarios into the system to train and evaluate physicians and health care teams in these and other topic areas:

Airway and Ventilator Management in the Critical Care Setting
Polysomnography
Pulmonary Function Testing
Invasive and Noninvasive Hemodynamic Monitoring
Shock Management in the Critical Care Unit
Ultrasoundography in the ICU

It appears that physician participation in this activity will satisfy the ABMS maintenance of certification requirements for documentation of clinical competence in our specialty. As part of their continuous quality improvement evaluation, both CMS and the ABMS will be looking for evidence that physicians are participating in patient registries to document efforts in self-evaluation and improvement in practice outcomes. Both have indicated that they will accept a physician’s participation in a professional society’s database as evidence of quality improvement activity. Several medical specialty societies have developed patient registries and quality improvement databases to assist their members with fulfilling their self-evaluation of practice performance requirements for the American Board of Internal Medicine (ABIM) maintenance of certification. Current medical societies with direct links to ABIM’s maintenance of certification program include the American College of Cardiology, and the American Board of Thoracic Surgery. Anticipating this government and public demand for documentation of quality, members of the ACCP Quality Improvement Committee (QIC) developed a proposal for an ACCP database and presented this to the Board of Regents meeting in July 2007. Following board approval, the committee entered into discussion with CECity, a provider of online continuing medical education, quality improvement, and outcomes programs. With technology designed specifically for health care, CECity’s processes and applications are fully compliant and meet HIPPA and CME guidelines. The initial project is focused on recording and procedural data, specifically fiberoptic bronchoscopy. The first stage has been implemented and, as the kinks are worked out, additional pulmonary-related categories will be added.

Participation in the CECity platform should provide several benefits. It is designed to simplify management and reporting of completion of certification data, state licensure information, and continuing medical education requirements. There will be access to reliable and secure information about individual practice strengths and areas that might need improvement. The College will provide opportunities to build skills and competencies with educational offerings that target areas where improvement is needed. For those of us in private practice, this program will provide readily available clinical data as a statistical aid in contract negotiations.

In addition to maintaining cutting-edge postgraduate education programs, it is the goal of the College leadership and committees to anticipate issues affecting care delivery to the patient. While working to ease the regulatory burdens on the clinician, the staff stands ready to act as a resource for physicians facing these problems. Feel free to call with questions at any time.

FEBRUARY 2009 • CHEST PHYSICIAN
Continued from previous page

2008; 133(suppl):1S. Less attention has been paid to the needs of people living in the community who are reliant on electricity to operate their crucial medical equipment. People requiring home positive pressure ventilation and/or oxygen (up to 1.8 million Americans) are particularly at risk during sustained power outages (Prezant et al. Crit Care Med 2005; 33(suppl):S96; Chatburn et al. Respir Care 2006; 51:232). While disaster planning is required for accredited home medical equipment (HME) agencies, this planning need not include a steady supply of oxygen during prolonged power outages. Hospital wards will be too full to be “medical sheltering” sites for oxygen-dependent patients. A single patient on 2L/min continuously will require approximately 5 E cylinders per day. To provide this level of support, pre-event planning is needed to provide back-up generators, oxygen conserving devices, and emergency management collaboration with HME organizations. In addition, respiratory clinicians should discuss disaster preparedness with their individual patients (see box below). ACCP Home Care and Disaster Response NetWorks are in collaboration with other professional societies and federal agencies and have embarked on a comprehensive approach to enhance disaster resiliency for patients with respiratory disease.

Dr. Lisa Wolfe, FCCP
Home Care NetWork
Steering Committee Member

Dr. Lewis Rubinson, FCCP
Member, Disaster Response NetWork

Interstitial and Diffuse Lung Disease
Health-Related Quality of Life in Patients With IPF: More Work To Be Done

Compared with general population norms, patients with idiopathic pulmonary fibrosis (IPF) have impaired health-related quality of life (HRQL) in nearly every domain assessed (Swigris et al. Chest 2005; 127:284) and dyspnea is one strong driver of that impairment (Nishiyama et al. Respir Med 2005; 99:408).

Investigators have used several instruments to measure HRQL in patients with IPF. HRQL scores tend to correlate significantly (and in the appropriate directions) with various concurrently collected clinical measures of IPF severity (eg, PVR, DLco). Despite a number of these cross-sectional, concurrent validity studies, a lingering question is what instrument(s) is “best” to assess HRQL in patients with IPF? If the goal is to capture within subject change in HRQL over time, or to compare change between groups (eg, in the context of a treatment trial), it is entirely unclear—data needed to answer the question are sparse.

Also lacking for IPF is a basic understanding of how to interpret changes in HRQL scores—a factor paramount to using HRQL as an outcome measure. Tomiska and colleagues (Intern Med 2007; 46:1533) have shed some light on this issue. In a study of 32 subjects with IPF, they found that certain SF-16 domains could discriminate subjects whose disease status changed over time. For example, among subjects whose vital capacity declined 10% (raw or percent predicted not stated) after a median 14 months from baseline, the SF-16 vitality domain score (which assesses energy/ppt) declined 16 points, indicating worsened HRQL; among subjects whose vital capacity remained stable or improved 10% from baseline, the score was unchanged, increasing by about 2 points. For patients with IPF, whether this 18-point difference is meaningful clinically is unknown. Establishing the minimum differences in HRQL scores that are clinically meaningful is important work that remains to be done. Only after such data are known can IPF trials be adequately powered for HRQL, and only then will we know, with reasonable certainty, whether interventions lead to meaningful change in this important outcome.

Dr. Jeffrey J. Swigris
Interstitial Lung Disease Program in the Autoimmune Lung Center
National Jewish Health; Denver, CO

Sleep Medicine
Advances in the science of sleep medicine will continue to radically transform the role of sleep and the various sleep disorders in the daily clinical practice and research activities of pulmonologists, cardiologists, and intensivists. Increasingly, chest clinicians and allied health professionals are being asked to manage patients with complaints of either sleeplessness or sleepiness, and the wide range of sleep disturbances between them, including sleep apnea, circadian rhythm sleep disorders, and parasomnias. Finally, many respiratory and cardiovascular disorders, such as asthma, COPD, restrictive lung diseases, and heart failure, can disturb sleep and alter sleep architecture. Sleep can be impaired by the medical conditions themselves or by the medications used to treat them.

The Sleep Medicine NetWork has several proposed projects that are designed to assist the College and its members with issues related to the field. With an emphasis on education and advocacy, and in collaboration with the other ACCP NetWorks and the ACCP-Sleep Institute, the Sleep Medicine NetWork’s proposed projects for 2009 include the management of sleep in the dying patient, and Webcasts on important topics, such as home sleep apnea testing.

Dr. Teafilo Lee-Chiong, FCCP
Sleep Medicine NetWork Chair

Disaster Planning Steps

1. Identify a “safe retreat” and provide phone numbers and locations to the DME.
2. If personal assistance is required, identify and train alternative care providers at the “safe retreat.”
3. Contact local public health or emergency management and find out if they have a medical needs disaster registry. If so, provide appropriate information to the registry.
4. Consider the use of portable oxygen concentrators that may allow for easier evacuation.
5. Develop a “Go Pack” with needed equipment, such as cannulas, suction catheters, nebulizers, extra PAP therapy masks, etc. Plan to take all of your nondisposable equipment, if possible.
6. Back-up power sources are essential; generators, car battery adapters, or marine batteries may all be helpful. These devices should be seen as a bridge to allow for easier evacuation.
7. Discuss with your respiratory provider oxygen conservation strategies—are any strategies safe for you and what are they?
8. Periodically, practice your disaster plan to ensure that you are best prepared for a real emergency.
On December 2, 2008, the Institute of Medicine’s (IOM) Committee on Optimizing Graduate Medical Trainee (Resident) Hours and Work Schedules to Improve Patient Safety released a compendium of recommendations regarding resident duty hours, patient safety, and supervision (http://books.nap.edu/openbook.php?record_id=12508&page=R1 [accessed December 31, 2008]). This report comes about 5 years after the current Accreditation Council for Graduate Medical Education (ACGME) regulations went into effect and provides a comprehensive review of the available literature. It also identifies where evidence is lacking. The committee’s report, funded by the National Academy of Sciences and the Agency for Healthcare Research and Quality (AHRQ), suggests further refinement of the 2003 ACGME duty hour standards and calls for further measures to reduce resident fatigue, improve patient handovers, and ensure adequate resident supervision and more research to quantify the effects on clinical outcomes and resident education.

The implementation of the 2003 ACGME regulations grew from public concern after a death felt to be related to resident fatigue occurred in a New York City hospital in 1984. Subsequently, the Bell Commission was established and delivered a report to the State of New York in 1987 (Final report, December 31, 2008). For example, “from the trenches” view. Many of those who complained of the 2003 regulations do not try to refute the goal of assuring adequate rest; rather, they are critical of good intentions and recommend further reductions to duty hours were recommended (80-h work week averaged over 4 weeks), with the acknowledgement that “regulating resident duty hours and increasing adherence to them would be insufficient to improve conditions for resident and patient safety” (http://books.nap.edu/openbook.php?record_id=12508&page=R1 [accessed December 31, 2008]). New measures to reduce fatigue were suggested. Notably, extended call shifts, defined as >16 h, must have 5 uninterrupted protected hours of sleep time between 10:00 PM and 8:00 AM in a “safe and sleep-conducive environment.” Residents should not admit patients after 16 h on any extended call shift and, after three or four consecutive shifts, a 48-h period off must be ensured. The ACGME mandatory time off allowances of 4 days per month and 1 day (24 h) per week (averaged over 4 weeks) has been changed to 5 days per 4 weeks, 1 day (24 h) per week (no averaging), and one 48-h period off. Clearly, then, adjustments to work hours have been recommended, but they have been ineffectively packaged and could result in scheduling mayhem and further detriment to patient care.

We are heartened by the IOM report’s renewed focus on resident supervision. The tension between education and service provision has been ongoing since medical training began. Ideally, supervision would be such that resident errors, whether secondary to fatigue or not, not reach the patient. Because of economic realities, physician teachers are not nearly numerous enough to achieve this. The IOM committee recommended that “the ACGME should ensure that residency programs provide adequate, direct, on-site supervision” and that “Residency Review Committees, in conjunction with teaching institutions and program directors, establish measurable standards of supervision for each level of physician in training, as appropriate to their specialty.” This is far easier said than done. The IOM also recommended developing system-wide face-to-face preferably electronic handoff tools that standardize communication and encourage “check list” type information exchange. Also, residency programs are encouraged to schedule adequate time during shift changes in order to foster effective communications.

From our perspective, most of the recommendations seem sensible. Yet, what will be the consequences of another round of changes in graduate medical education (intended and unintended)? In a medical world that is supposed to be “evidence-based” and that “Residency Review Committees” view, “there are simply too few data to reliably estimate the extent to which errors in performance by fatigued residents affect patients and cause them harm” (http://books.nap.edu/openbook.php?record_id=12508&page=R1 [accessed December 31, 2008]).

To its credit, the IOM’s committee encourages research to answer these questions, education to reduce the risks inherent in its recommendations, and funding to support the changes. The committee also proposed that other agencies, such as but not limited to the Centers for Medicare and Medicaid Services and The Joint Commission, add duty hour reviews to their site visits. But if history (2003) is any lesson, a focus on duty and sleep hours will take center stage, while research and funding will languish. Legislation was introduced in Congress to ensure funding for changes contemplated...
CHEST Launches New Online Platform, New Look for 2009

CHEST started 2009 off with a bang, as it migrated to a new Web 2.0 platform in January. The more robust and enhanced platform contains many new features and an improved layout and design.

The innovations are highlighted by the inauguration of a highly anticipated new section: Interactive Physiology Grand Rounds, edited by Michael J. Parker and Richard M. Schwartzstein. This series will feature interactive animated diagrams that are an important part of each article and will help to improve the understanding of the underlying physiology related to each case.

An editorial introducing the new section, and the section’s first submission, can be found in the January 2009 issue of CHEST. The animations are viewable online at www.chestjournal.org.

Dr. Richard S. Irwin, FCCP, comments: “The launch of the new Web platform and Interactive Physiology Grand Rounds with animated diagrams are features that were conceived to transform CHEST into becoming a Journal of the Future. As defined during a 2007 strategic planning meeting of the Associate Editors and described in one of our recent editorials (Irwin RS, Welch SJ. Becoming the journal of the future. CHEST 2008; 133: 1-3), a successful journal of the future will need to publish content that will be meaningful and essential to a more diverse group of readers and subject matter that is easier and faster to read and access. It will also need to find ways to enhance teaching.

“We believe that the launch of these new features meets the spirit of this definition.”

PCCU Lessons for February

www.chestnet.org/education/online/pccu/index.php

PCCU Lessons for January

- Management of Pulmonary Complications in the Patient With Cystic Fibrosis. By Dr. Patrick A. Flaherty, FCCP
- Fibroiliac Mediastinitis: Causes, Diagnosis, and Treatment. By Dr. Meredith W. Pugh; and Dr. James E. Leyd

PCCU Lessons for February

- Cognitive and Functional Outcomes After ICU Admission. By Ramona O. Hopkins, PhD; and James C. Jackson, PsyD
- Noninfectious Pulmonary Diseases in HIV. By Dr. Kristina A. Crothers, FCCP; Dr. Lawrence Huang, FCCP; and Dr. Alison M. Marris

Continued from previous page

in 2003, however, the bill was not passed.

We recommend a cautious (walk, don’t run!) approach, advocating well-conducted innovative pilot trials to enhance resident and patient safety before another wholesale (and possibly ineffective) reengineering of our nation’s program for training doctors is implemented.

Unfortunately, it would appear that the ACGME may do just that and has indicated that “in early March 2009, the ACGME is convening a duty hours conference that will bring together leaders in graduate medical education from around the world” (www.acgme.org/acWebsite/newsReleases/newsRe12_2_08.asp [accessed December 31, 2008]).

Taking another leap of faith and assuming that restructured hours will result in less fatigued residents and will translate into safer patient care will be costly and potentially dangerous. We must instead emphasize and fund process improvements so that our training programs will have the requisite personnel for superior trainee supervision, quality software to enable effective and structured handovers, and the research necessary to know that we are improving rather than damaging care.

Dr. John K. McIwaine, FCCP
University of Massachusetts
UMass Memorial Medical Center
Worcester, MA

Dr. Stephen M. Pastores, FCCP
Memorial Sloan-Kettering Cancer Center
New York, NY

Dr. Gregory A. Schmidt, FCCP
University of Iowa Hospitals and Clinics
Iowa City, IA

Dr. William R. Andrews, FCCP
Memorial Hermann Hospital-Texas Medical Center
Houston, TX

This Month in CHEST: Editor’s Picks

By Dr. Richard S. Irwin, FCCP
Editor in Chief, CHEST

- Effect of Specific Allergen Inhalation on Serum Adiponectin in Human Asthma. By Dr. A. Seed, FCCP, et al.
- Reliability of a 25-item Low-Stakes Multiple Choice Assessment of Bronchoscopic Knowledge. By Dr. S. Quadralli, FCCP, et al.

Clinical Commentary


www.chestjournal.org

Simulation Education, Real Results.

ACCP Simulation Center for Advanced Clinical Education
Northbrook, Illinois

Don’t Miss These Sessions
- Work and Interpersonal Skills with a Focus on Enhancing Interpersonal Skills
- Evidence-based patient care
- Research-based procedures
- Current standards of practice

Register now.
www.chestnet.org/simulation

Attend a hands-on, clinical learning experience:
- Experience with simulation for all levels
- Subject matter is designed to fit all training levels
- Experience is designed to be safe and fun

Clinical Commentary

- Comorbidities and cancer, the interaction of drugs, and the effects of surgery on patients
- Strategies for dealing with the patient and the family
- Realistic scenarios

This 3-day simulation-enhanced workshop will provide hands-on experience with simulation, teamwork, and tools to manage common and complex airway situations.

Human Patient Simulator (HPS): Basic and Advanced Courses
May 4-7, 2009
This 4-day course is intended for the emergency care practitioner and emergency department nurse.

Emergency Care Simulator (ECS): Basic and Advanced Courses
May 12-13, 2009
This 4-day course is intended for the emergency care practitioner and emergency department nurse.
ACCP membership offers you an opportunity to apply for one of The CHEST Foundation awards. Whether your area of expertise is research in critical care, lung cancer, women’s health, or AAT deficiency and COPD, leadership in end-of-life care; or humanitarian service; The CHEST Foundation offers 1- and 2-year awards to ACCP members who meet the qualifications of one of the many 2009 awards available.

The Third Eli Lilly and Company Distinguished Scholar in Critical Care Medicine award is open to ACCP members who are FCCPs in the area of critical care medicine. The successful candidate will have a 3-year opportunity to examine issues that are not easily supported by traditional funding, such as the development of public policy, patient education models, or economic analysis of treatment or care delivery in this patient group. This award grants $160,000 over the course of 3 years for a project or program that relates to the treatment of critically ill patients.

The research awards, granted to ACCP members who submit outstanding research projects in various areas of chest medicine, reflect the multidisciplinary nature of the ACCP.

In 2009, The CHEST Foundation offers a variety of clinical research awards in the areas of geriatric development, lung cancer, COPD and alpha-1 antitrypsin (AAT) deficiency, and women’s health. The 2009 research opportunities also reflect the continuing partnerships of The CHEST Foundation with the Association of Specialty Professors, the LUNGevity Foundation, and the Alpha-1 Foundation.

Focusing on the important area of critical care, The CHEST Foundation continues to acknowledge outstanding leadership in end-of-life care through the Roger C. Bone Advances in End-of-Life Care Award. The year 2009 marks the ninth year that this prestigious award will be granted to an ACCP member involved in palliative and/or end-of-life care. Members of the Palliative and End-of-Life Care NetWork serve on the review committee.

The CHEST Foundation’s D. Robert McCaffree, MD, Master FCCP Humanitarian Awards, formerly known as The CHEST Foundation Humanitarian Recognition Awards and Project Development Grants, support the volunteer efforts of those who generously give their time and medical expertise to improve the health of people living in communities around the world.

Since 1998, The CHEST Foundation has awarded over $1.3 million in awards given to nonprofit and nongovernmental organizations where ACCP members focus their pro bono services. The new 2009 award is open to ACCP members involved in the care of ventilator technology-dependent children.

NEW for 2009: The CHEST Foundation will grant awards in the amounts of $5,000, $10,000, and $15,000. Those applying for the $10,000 and $15,000 grants will be required to complete a more extensive application and submit additional documentation with their completed application. The DEADLINE FOR ALL 2009 AWARDS IS APRIL 30, 2009.

For requirements and candidate qualifications, go to www.chestfoundation.org. Click on Clinical Research Awards, Humanitarian Awards, or Critical Care on the top bar.

**Value of The CHEST Foundation’s Awards Program. . .**

**in the Words of Previous Award Recipients**

Dr. Martin L. Bauer, FCCP

**$25,000 Humanitarian Project Development Grant 2007 Recipient**

Camp Aldersgate Summer Medical Camp for Ventilator Technology-Dependent Children

The specific aims of his project were the following: (1) to provide a 1-week camp experience at Camp Aldersgate in Little Rock, AR, for ventilator technology-dependent (VTD) children; (2) to stage severity of air-flow limitation and, hence, COPD, according to the FEV1/FVC ratio that is defined by mortality risk, and (2) to provide facilities, personnel, and equipment to support the care of VTD children while they attend summer camp.

Funds provided by The CHEST Foundation Humanitarian Award allowed installation of additional electrical circuitry to accommodate 16 VTD campers, their medical buddies, equipment, equipment storage, and equipment cleaning in two cabins. These cabins are specifically designed for wheelchair and disability access, each with a specially designed shower and bathroom facilities, spacious sleeping rooms with space for hospital beds, and a large screened porch. They are climate-controlled, allowing year-round use. These cabins provided the facilities to house the VTD children.

The first camp experience was provided in conjunction with the Muscular Dystrophy summer camp. Three VTD youth with muscular dystrophy attended the camp June 8-13, 2008.

Dr. Bauer noted that the most obvious impact was on the campers and their families. He said that the families provided their VTD children an experience away from parents in an environment supportive of ventilation technology. The VTD campers reveled in the new independence and freedom that they thought they had lost when they could no longer breathe adequately on their own. Other campers saw and appreciated the beneficial impact that ventilation could have on their lives in the future.

This first summer camp for VTD children convinced the dedicated volunteer staff members that a first-class camp experience can, indeed, be provided for these children. They are now investigating services for VTD children with invasive, as well as noninvasive, interface and those with diseases other than muscular dystrophy as children younger than 8 years of age. They are also considering weekend respite opportunities throughout the year.

Dr. Carlos A.V. Fragoso, FCCP

Association of Specialty Professors and The CHEST Foundation of ACCP Geriatric Development Research Award Recipient 2007

Establishing Chronic Obstructive Pulmonary Disease in Older Persons

The specific aims of his project were the following: (1) to establish airflow limitation based on a lower limit of normal for the FEV1/FVC ratio that is defined by mortality risk, and (2) to stage severity of air-flow limitation and, hence, COPD, according to the FEV1/FVC expressed as a standardized residual percentage. He has completed the first year of his 2-year award.

Dr. Fragoso writes, “I wish to express my gratitude for the support provided by the ASP/CHEST Foundation. This has been an important step in my career development, as it has allowed me to pursue further training in skills necessary for becoming an independent investigator and to successfully compete for a VA Career Development Award.

In addition, our research may improve patient care regarding COPD in older persons. Specifically, by distinguishing persons with a higher likelihood of death or of being symptomatic from those with airflow limitation alone, our definition of COPD could lead to a more efficient use of diagnostic and therapeutic services.”

www.chestfoundation.org
Participants in the CHEST 2008 5K Lung Health Walk/Run were ALL winners. Those who placed first, second, or third place are listed below.

**Category**
- Oldest Female Runner
- Oldest Male Runner
- 1st Place Male 29 and under
- 2nd Place Male 29 and under
- 3rd Place Male 29 and under
- 1st Place Female 30 - 39
- 2nd Place Female 30 - 39
- 3rd Place Female 30 - 39
- 1st Place Male 50 - 59
- 2nd Place Male 50 - 59
- 3rd Place Male 50 - 59
- 1st Place Female 50 - 59
- 2nd Place Female 50 - 59
- 3rd Place Female 50 - 59
- 1st Place Male 60 - 69
- 2nd Place Male 60 - 69
- 3rd Place Male 60 - 69
- 1st Place Female 60 - 69
- 2nd Place Female 60 - 69
- 3rd Place Female 60 - 69
- 1st Place Male 70 - 79
- 2nd Place Male 70 - 79
- 3rd Place Male 70 - 79
- 1st Place Female 70 - 79
- 2nd Place Female 70 - 79
- 3rd Place Female 70 - 79

Note: Caleb Edmonds and Lee Edmonds came in first and second place overall and did not give their ages. They also left immediately.

**Note:** Caleb Edmonds and Lee Edmonds came in first and second place overall and did not give their ages. They also left immediately.

**11th Annual Awards**

**First Place Female 60 - 69**
- No winner

**3rd Place Female 50 - 59**
- No winner

**2nd Place Female 50 - 59**
- No winner

**1st Place Female 50 - 59**
- Anne Marie Geneser

**2nd Place Female 40 - 49**
- Mojdeh Talebian

**1st Place Female 40 - 49**
- Amy Jenkins

**2nd Place Female 30 - 39**
- Danira Mayes

**1st Place Female 30 - 39**
- Amy Spence

**2nd Place Female 29 and under**
- No winner

**1st Place Female 29 and under**
- Amy Jenkins

**2nd Place Male 60 - 69**
- Pierre Mocostabella

**2nd Place Male 50 - 59**
- Allan Davidson

**1st Place Male 50 - 59**
- Ben Foy

**3rd Place Male 40 - 49**
- Michael Boyd

**2nd Place Male 40 - 49**
- Timothy Quast

**2nd Place Male 30 - 39**
- Nathan Hatton

**1st Place Male 30 - 39**
- Danira Mayes

**2nd Place Male 29 and under**
- No winner

**1st Place Male 29 and under**
- Amy Jenkins

**Oldest Female Runner**
- Monir Almassi

**Humanitarian Recognition**
- $5,000 Ambassadors Group
  - Francis J. Podbielski, MD, FCCP
  - Parthasarathi Bhattacharyya, MD, FCCP

**Humanitarian Award**
- $5,000 Humanitarian
  - Gregory Efosa Erhabor, MD, FCCP
  - The CHEST Foundation
  - Henry I. Bussey, PharmD, FCCP
  - Distinguished Scholar
    - Volunteer work related to chest and critical care medicine. Congratulations to these winners.

**CHEST 2008 Bingo Winners**

**PRODUCT OF THE MONTH**

**Prevention of Venous Thromboembolism in Hospitalized Patients**

This CME activity consists of a print supplement (supplement to the February CHEST Physician issue) with three sections: (1) pretest questions designed to emphasize the learning objectives; (2) description of the current gap in performance and need for increased education in the area of venous thromboembolism (VTE) prevention; and (3) a review of the epidemiology and prevalence of VTE in hospitalized medical patients, a review of the evidence behind current recommendations, and a review of the current ACCP recommendations for VTE prevention in hospitalized medical patients.

Several months after release of the monograph, readers will be able to access an online link to case scenarios in which the application of their knowledge in VTE prevention will be tested. This will be ACCP-SICK-type questions. CME credit will be provided.

**Congratulations to The CHEST Foundation’s 2008 Award Winners**

**Distinguished Scholar**
- The Second Glenn Fleisher Distinguished Scholar in Thrombosis
  - Henry J. Busay, PharmD, FCCP

**The CHEST Foundation Humanitarian Awards**
- $25,000 Project Development Grant Winners
  - Yassen Arab, MD, FCCP
  - Henry J. Busay, PharmD, FCCP
  - Gregory Eliahu Khulthu, MD, FCCP
  - Rafael Laredo-Lemons, MD, FCCP

- $5,000 Humanitarian Recognition Award Winners
  - Pangandaran Harto, MD, FCCP
  - Lorez Jean-C, Caberos, MD, FCCP
  - Francis J. Puthilkal, MD, FCCP
  - Avessa M. Mokemen, MD, FCCP

- $5,000 Ambassadors Group Humanitarian Recognition Award Winner
  - G. Lakshmi, MD, FCCP

**Annual Awards**
- The American Society of Hematology
  - The CHEST Foundation
  - Foundation Gestocon Clinical Development Research Award
  - Jeffer C. Hosert, MD, FCCP
  - Shirley Y. Jones, MD, FCCP

- The Alpha-1 Foundation and The CHEST Foundation Clinical Research Award in COPD and Alpha-1 Antiprotein (AA1)
  - Amy Shalifare, MD, FCCP

- The American Society of Transplantation and The CHEST Foundation Clinical Research Award in Lung Transplantation
  - Sharon F. Chen, MD

- The CHEST Foundation and The LUNGevity Foundation Clinical Research Award in Lung Cancer
  - Scott L. Sheller, MD, PhD

- Christopher G. Stetons, MD, MS

- The CHEST Foundation and Boehringer Ingelheim Pharmaceuticals Inc. Clinical Research Award in Women’s Pulmonary Health
  - Subhan Dhandia, MBBS
  - Margaret A. Pau, MD, FCCP

- The CHEST Foundation California Chapter Clinical Research/Medical Education Award
  - Henn G. Cohl, MD, FCCP

- **Young Investigator Award Winners**
  - **$2,275**
    - CAPT James P. Woodward, MC, USA
    - Anne Gonzales, MD
    - Gustavo Hen, MD

- **$775**
  - Juan T. Sanchez, MD
  - Bhavnesh K. Sharma, MD
  - Adrinos R. Tonik, MD
  - Sebastian A. Dranitsis, MD
  - Suhail Naq, MD
  - Justin J. Baker, MD
  - Sushma K. Cribbs, MD

- **Top Five Posters Awards**
  - Sadheer Kand, MD, FCCP
  - Marjolijn Rijmens, MD, FCCP
  - Richard C. Redman, MD
  - Barbara A. Phillips, MD, FCCP
  - Saifullah Khan, MBBS, MD

- **Case Report Award Winners**
  - David Green, MD
  - Verne Damlwanakoda, MD
  - Anne Kim, MD
  - Apkana Prasad, MD
  - Jess Thompson, MD
  - Alcides Lmaque, MD
  - Jason-Calbott, MD
  - Paul Hefferman, MD
  - Brian Garfield, MD
  - Meghan McCulloch, MD
  - Jason Blower, MD
  - Ghanasingh Azach, MD
  - Juan Sanchez
  - Suman Kossell, MD
  - CAPT James P. Woodward, MC, USA
  - Chackwarty Reddy, MD
  - Joel Mirmar, MD
  - Shaloo Alazan, MD
  - Alexis Gifford, MD
  - Subhan Dhandia, MBBS
  - Anita Shuk, DO
  - Michael Felcins, MD
  - Paul Wisco, MD
  - Sunil Rajan, MD

**Congratulations to the CHEST Challenge Winners**

The top three teams from the CHEST Challenge competed in a 24-hourDataRow challenge and won cash prizes for their institutions. Congratulations to these teams.

**First Place**
- National Capital Consortium Pulmonary and Critical Care Fellowship Program
  - CAPT Christopher R. King, MC, USA
  - UCD Timothy M. Quaint, MC, USA
  - CAPT James P. Woodward, MC, USA

**Second Place**
- Maimonides Medical Center
  - Ahmed A. Hrahboglu, MBBS
  - James J. Andrysh, MBBS
  - Yarin R. Melnick, MD

**Third Place**
- University of Connecticut
  - Binshua/Niemanwoman, MBBS
  - Shing Eleonora, USA
  - Aydin Upay, MD

**2009 Awards Program**

The tradition of supporting research and volunteer work related to chest and critical care medicine will continue in 2009. Watch for application details at www.chestfoundation.org.

**ACCP Worldwide:**

ACCP reaches out at Brazilian conference

The XXXIV Brazilian Congress of Neumology and Tisutology (held in conjunction with the VI ALAT (Associação Latinoamericana do Tórax)) meeting and the V Portugueses-Brazilian Congress of Neumology was held in Brazil, Brazil, on November 21-24, 2008.

Dr. Alvim Thomas, Jr., FCCP and Dr. M. Patricia Riveria, FCCP served as faculty during this ACCP-endorsed educational event.

With about 2,000 attendees, this was the largest conference on thoracic diseases in Latin America, and the ACCP booth benefited from solid and constant activity throughout the meeting. As ACCP members and nonmembers came to find out about our latest offerings.

This was an excellent opportunity to strengthen ties with the SBPT (Sociedade Brasileira de Pneumologia e Tisutologia) leadership and expand awareness of ACCP products and services among the Brazilian and Latin American participants.
Breath-Hold CT Improved Lung Tumor Sizing

BY PATRICE WENDLING
Elsevier Global Medical News

CHICAGO — Adding a breath-hold chest CT to a standard shallow-breathing PET-CT study improved the accuracy of sizing primary lesions and detection of additional small pulmonary nodules in a retrospective study of 50 consecutive patients with suspected or known lung cancer.

In 6 (12%) of 50 patients, a radiology resident found a 2-mm or more difference in primary axial tumor size when measured by shallow-breathing CT versus breath-hold CT. An experienced attending radiologist found such a difference in 18% of patients.

The largest measured size difference was 10 mm (mean size 3.3 mm, range 3-10 mm). In all cases where a size difference was reported, the measured size was larger on the breath-hold CT. Dr. Vinay Ravi and colleagues reported at the annual meeting of the Radiological Society of North America.

With breath-hold CT, an additional 15 pulmonary nodules were detected that were missed on the shallow-breathing PET/CT scan, the largest of which was 9 mm in size (mean 4 mm, range 3-9 mm). Two nodules were located in the upper lobe of the lung, 3 in the middle lobe, and 10 in the lower lobe nearest the diaphragm.

A continuous, shallow-breathing PET/CT study has become the standard-of-care imaging test for evaluating patients with lung cancer, but respiratory motion can play havoc with the evaluation of the lung parenchyma on CT images, said Dr. Ravi, a second-year radiology resident at Dartmouth University, Lebanon, N.H. Respiratory motion can blur the images and cause attenuation-related errors that can be severe near the diaphragm.

The interpretation of PET images is not significantly compromised by respiratory motion, but PET has limited sensitivity for subcentimeter lesions, which limits the characterization of small pulmonary nodules. The incidence of malignancy in subcentimeter nodules ranges from 10% to 58% in published reports.

In the current series, the identification of additional nodules with breath-hold CT impacted clinical management in 75% of cases read by the attending radiologist, Dr. Ravi said. None of the additional nodules detected by breath-hold CT had visible FDG (18F-fluorodeoxyglucose) uptake on PET.

“We believe that a separate breath-hold CT when obtained as part of a shallow-breathing PET-CT study may result in more precise size measurement of the primary lesion and improved detection and characterization of additional small pulmonary nodules, and thus may very well affect clinical staging and management,” he said.

When asked by the moderators, however, if any of the attendees read PET and CT scans separately or charged for an independent CT, none raised their hands.

The overuse of CT has become an issue in the medical community, but Dr. Ravi said in an interview that adding a breath-hold CT would increase the radiation dose by only about 2-3 mSv. “I do not believe that this is a limiting factor,” he said.

Although the study was limited by the fact that shallow-breathing PET-CT images were interpreted prior to breath-hold CT in all cases, its findings confirm those of two previous studies.

In a recent study performed at Memorial Sloan-Kettering Cancer Center in New York, breath-hold CT detected significantly more lesions than did clinical CT in 13 (87%) of 15 patients with suspected pulmonary lesions, increasing the total number of lung lesions detected from 53 with clinical CT to 82 with breath-hold CT (J. Nucl. Med. 2007;48:712-9).

Breath-hold CT detected an additional 125 parenchymal lung nodules in 34% of 142 consecutive patients evaluated with PET/CET for staging and restaging of various types of cancer at the University of California at Los Angeles. On average, three nodules were missed during shallow-breathing CT (J. Nucl. Med. 2006;47:298-301).

Fewer additional nodules were detected in the current study than in those two studies, likely because of the use of a more sophisticated 16-channel multideector PET-CT system (GE Discovery ST) for the shallow-breathing studies, Dr. Ravi explained.

PET-CT findings were used to diagnose lung cancer in 8 patients, for initial staging in 11, and for restaging in 31. The patients’ mean age was 65 years, and 26 were men.

The investigators received no funding for the study and had no conflicts of interest to disclose.

Dr. W. Michael Alberts, FCP, comments: A necessary companion study should investigate whether discovering additional nodules or more accurately measuring known nodules provides any clinical benefit—or whether it merely adds to the clinical challenge of dealing with false-positive findings.
Obstructive sleep apnea and its associated comorbid conditions show a distinct age-related pattern, peaking in very young children and in older adults.

The lowest incidence occurs in adolescence, when the pharynx has grown enough to accommodate lymphoid tissue and obesity is at a lifetime low. Qi Huang of the University of Sydney and his associates reported in the Dec. 15 issue of the Journal of Clinical Sleep Medicine (2008;4:543-50).

Dr. Huang of the University of Sydney and his associates extracted their information from Australia’s New South Wales Inpatient Data Collection system (1994-2004), which contains a representative collection of hospital records in the territory. Of the 1.5 million patient records examined, 4% (60,200) showed obstructive sleep apnea (OSA) as either a primary or secondary diagnosis. A total of 72% of the patients were male, and males predominated in every age group.

The occurrence of OSA was elevated in children aged 0-4 years (9% males, 6% females) and declined to a low at 15-24 years (1% of each gender).

THE RESEARCHERS SPECULATED THAT GENDER DIFFERENCES MIGHT RELATE TO A LESS STABLE AIRWAY IN MALES, BEGINNING IN PUBERTY.

After 24 years, the occurrence rose linearly in both genders, reaching a peak at ages 55-59 years (13% males, 12% females). Thereafter, a sharp decline occurred; by 85 years, OSA was present in only 1% of each gender.

The analysis also revealed a number of associated comorbidities. Most frequent were essential hypertension (18% of the cohort), obesity (14%), type 2 diabetes (12%), chronic ischemic heart disease and chronic obstructive lung disease (8% each), and hypercholesterolemia (7%).

Other conditions commonly seen were a history of tobacco use, congestive heart failure, atrial fibrillation or flutter, and coronary artery bypass graft.

Comorbidities also showed an age-related pattern, and were more common in males. Obesity rose after 25 years, peaking at 50-59 years, while diabetes peaked at 65-69 years. Hypertension peaked around age 55 years and remained increased until age 69 years for men and 74 years for women.

The researchers speculated that gender differences might relate to a less stable airway in males, beginning in puberty. “Boys have a longer upper airway length than girls, even when normalized for body height, and an increased airway length predisposes to pharyngeal collapse,” they wrote.

The increased incidence in young children probably has to do with the rapid growth of lymphoid tissue, which outpaces nasopharyngeal development, while the increase in OSA after age 25 years correlates with the increase in obesity, they suggested.

Cardiovascular comorbidities are probably more related to obesity patterns than they are directly tied to OSA, the team noted. The sharp drop-off in OSA incidence after age 65 years may reflect mortality associated with the comorbidities.
Introducing the First Generic Epoprostenol Sodium for Injection

AP Rated, Bioequivalent and Therapeutically Equivalent to Flolan®* for Injection

An economical choice for your patients

*Flolan® is a registered trademark of SmithKline Beecham Corp.
©2008, Teva Pharmaceuticals USA

Good People, Good Products, Good Chemistry®

19 Hughes • Irvine, California 92618
800.729.9991 • www.tevausa.com

1988A